文献速递湿疹皮炎与荨麻疹

乌帕替尼治疗青少年中重度特应性皮炎:三项随机临床试验分析

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2023-01-01

该预设分析纳入3项随机双盲安慰剂对照3期试验中的552名12至17岁中重度特应性皮炎青少年,随机接受乌帕替尼15 mg、30 mg或安慰剂(联合或不联合外用糖皮质激素)。第16周时,乌帕替尼组达到EASI 75和vIGA-AD 0/1的比例均高于安慰剂组,安全性总体良好,痤疮为最常见不良事件且均为轻中度。

要点

  • 第16周EASI 75应答率:乌帕替尼15 mg为63%-73%,30 mg为73%-84%,安慰剂为12%-30%。
  • 乌帕替尼组vIGA-AD 0/1应答率和生活质量改善均优于安慰剂组。
  • 痤疮为最常见不良事件,所有痤疮事件均为轻中度。

核心结论

  • 在这项纳入3项随机临床试验的分析中,乌帕替尼是青少年中重度特应性皮炎的有效治疗,安全性可接受。

研究设计与样本

  • 对2018年7月至2020年12月在欧洲、南北美洲、大洋洲、中东和亚太地区20多个国家开展的3项随机双盲安慰剂对照3期临床试验(Measure Up 1、Measure Up 2和AD Up)中入组的青少年进行预设分析。
  • 共552名12至17岁中重度特应性皮炎青少年被随机分组(290名女性,262名男性)。
  • 患者按1:1:1随机接受每日一次口服乌帕替尼15 mg、乌帕替尼30 mg或安慰剂单用(Measure Up 1和Measure Up 2)或联合外用糖皮质激素(AD Up)。
  • 数据分析于2021年4月至8月进行。

主要发现

  • 在Measure Up 1、Measure Up 2和AD Up中,第16周达到EASI 75的青少年比例(%[95%CI])分别为:乌帕替尼15 mg组73%[63%-84%]、69%[57%-81%]、63%[51%-76%];乌帕替尼30 mg组78%[68%-88%]、73%[62%-85%]、84%[75%-94%];安慰剂组12%[4%-20%]、13%[5%-22%]、30%[19%-42%];所有与安慰剂的比较名义P值均<.001。
  • 与安慰剂相比,更多接受乌帕替尼治疗的青少年在第16周达到vIGA-AD评分0或1,并出现生活质量改善。
  • 乌帕替尼在青少年中总体耐受良好,痤疮为最常见不良事件,所有痤疮事件均为轻中度。
  • Measure Up 1、Measure Up 2和AD Up中青少年的平均(SD)年龄分别为15.4(1.8)岁、15.5(1.7)岁和15.3(1.8)岁。

关键数值与推荐

  • 共同主要终点为第16周时EASI较基线改善至少75%以及vIGA-AD评分为0(清除)或1(几乎清除)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atopic dermatitis onset usually occurs in childhood. Persistence of disease into adolescence and adulthood is common. It is important to evaluate new treatment options in adolescents because of the high unmet need in this population. OBJECTIVE: To assess the efficacy and safety of upadacitinib to treat moderate-to-severe atopic dermatitis in adolescents. DESIGN, SETTING, AND PARTICIPANTS: Prespecified analysis of adolescents enrolled in 3 randomized, double-blind, placebo-controlled phase 3 clinical trials in more than 20 countries across Europe, North and South America, Oceania, the Middle East, and the Asia-Pacific region from July 2018 through December 2020. Participants were adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis. Data analysis was performed from April to August 2021. INTERVENTIONS: Patients were randomized (1:1:1) to once-daily oral upadacitinib 15 mg, upadacitinib 30 mg, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up). MAIN OUTCOMES AND MEASURES: Safety and efficacy, including at least a 75% improvement in the Eczema Area and Severity Index from baseline and validated Investigator Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear) at week 16 (coprimary end points). RESULTS: A total of 552 adolescents (290 female; 262 male) were randomized. Mean (SD) age was 15.4 (1.8), 15.5 (1.7), and 15.3 (1.8) years for adolescents in Measure Up 1, Measure Up 2, and AD Up, respectively. In Measure Up 1, Measure Up 2, and AD Up, respectively, a greater proportion of adolescents (% [95% CI]) achieved at least 75% improvement in the Eczema Area and Severity Index at week 16 with upadacitinib 15 mg (73% [63%-84%], 69% [57%-81%], 63% [51%-76%]), and upadacitinib 30 mg (78% [68%-88%], 73% [62%-85%], 84% [75%-94%]), than with placebo (12% [4%-20%], 13% [5%-22%], 30% [19%-42%]; nominal P < .001 for all comparisons vs placebo). Similarly, a greater proportion of adolescents treated with upadacitinib achieved a validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 at week 16 and improvements in quality of life with upadacitinib than with placebo. Upadacitinib was generally well tolerated in adolescents. Acne was the most common adverse event, and all acne events were mild or moderate. CONCLUSIONS AND RELEVANCE: In this analysis of 3 randomized clinical trials, upadacitinib was an effective treatment for adolescents with moderate-to-severe atopic dermatitis, with an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2), and NCT03568318 (AD Up).

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023. PMID: 37043227. doi:10.1001/jamadermatol.2023.0391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。